Bristol Myers Squibb (CELG-RI) Other Non-Current Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Other Non-Current Assets of $6.1 billion for Q1 2026, up 3.68% YoY from $5.9 billion in Q1 2025, and down 6.05% sequentially from $6.5 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $6.1 billion for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 3.68% year-over-year to $6.1 billion; the TTM figure through Mar 2026 stood at $6.1 billion (up 3.68% YoY), while the FY2025 annual figure was $6.5 billion, up 6.04% from the prior year.
- Other Non-Current Assets declined to $6.1 billion in Q1 2026, from $6.5 billion in the prior quarter.
- Over the last five years, Other Non-Current Assets for CELG-RI reached as high as $6.5 billion in Q4 2025 and fell as low as $53.0 million in Q1 2023.
- The 5-year median for Other Non-Current Assets is $5.9 billion (2025), against an average of $3.9 billion.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 97.06% — and 2024, when it soared 11354.72%.
- A 5-year view of Other Non-Current Assets shows it stood at $4.9 billion in 2022, then advanced by 8.7% to $5.4 billion in 2023, then rose by 13.69% to $6.1 billion in 2024, then advanced by 6.04% to $6.5 billion in 2025, then slipped by 6.05% to $6.1 billion in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $6.1 billion, $6.5 billion, and $6.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | 6.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.08 Bn |
| Dec 31, 2025 | 6.47 Bn |
| Sep 30, 2025 | 6.33 Bn |
| Jun 30, 2025 | 5.94 Bn |
| Mar 31, 2025 | 5.87 Bn |
| Dec 31, 2024 | 6.11 Bn |
| Sep 30, 2024 | 6.04 Bn |
| Jun 30, 2024 | 6.07 Bn |
| Mar 31, 2024 | 6.02 Bn |
| Dec 31, 2023 | 5.37 Bn |
| Sep 30, 2023 | 54.00 Mn |
| Jun 30, 2023 | 53.00 Mn |
| Mar 31, 2023 | 53.00 Mn |
| Dec 31, 2022 | 4.94 Bn |
| Sep 30, 2022 | 223.00 Mn |
| Jun 30, 2022 | 210.00 Mn |
| Mar 31, 2022 | 210.00 Mn |
| Dec 31, 2021 | 5.54 Bn |
| Sep 30, 2021 | 339.00 Mn |
| Jun 30, 2021 | 373.00 Mn |